540 related articles for article (PubMed ID: 33162330)
1. Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
Mountzios G; de Toma A; Economopoulou P; Friedlaender A; Banini M; Lo Russo G; Baxevanos P; Roila F; Banna GL; Christopoulou A; Jimenez B; Collazo-Lorduy A; Linardou H; Calles A; Galetta D; Addeo A; Camerini A; Pizzutilo P; Kosmidis P; Garassino MC; Proto C; Signorelli D; Metro G
Clin Lung Cancer; 2021 Mar; 22(2):e180-e192. PubMed ID: 33162330
[TBL] [Abstract][Full Text] [Related]
2. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Kawachi H; Tamiya M; Tamiya A; Ishii S; Hirano K; Matsumoto H; Fukuda Y; Yokoyama T; Kominami R; Fujimoto D; Hosoya K; Suzuki H; Hirashima T; Kanazu M; Sawa N; Uchida J; Morita M; Makio T; Hara S; Kumagai T
Invest New Drugs; 2020 Feb; 38(1):211-218. PubMed ID: 31784866
[TBL] [Abstract][Full Text] [Related]
3. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
Cortellini A; Cannita K; Tiseo M; Cortinovis DL; Aerts JGJV; Baldessari C; Giusti R; Ferrara MG; D'Argento E; Grossi F; Guida A; Berardi R; Morabito A; Genova C; Antonuzzo L; Mazzoni F; De Toma A; Signorelli D; Gelibter A; Targato G; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Filetti M; Bracarda S; Citarella F; Russano M; Cantini L; Nigro O; Buti S; Minuti G; Landi L; Ricciardi S; Migliorino MR; Natalizio S; Simona C; De Filippis M; Metro G; Adamo V; Russo A; Spinelli GP; Di Maio M; Banna GL; Friedlaender A; Addeo A; Pinato DJ; Ficorella C; Porzio G
Eur J Cancer; 2021 May; 148():24-35. PubMed ID: 33721704
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
Velcheti V; Chandwani S; Chen X; Piperdi B; Burke T
Clin Lung Cancer; 2020 Sep; 21(5):e445-e455. PubMed ID: 32376116
[TBL] [Abstract][Full Text] [Related]
5. Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.
Morita M; Tamiya M; Fujimoto D; Tamiya A; Suzuki H; Hirano K; Fukuda Y; Yokoyama T; Kominami R; Kanazu M; Uchida J; Hara S; Yamashita S; Tomioka H
BMC Cancer; 2020 Feb; 20(1):93. PubMed ID: 32013910
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
[TBL] [Abstract][Full Text] [Related]
7. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.
Aguilar EJ; Ricciuti B; Gainor JF; Kehl KL; Kravets S; Dahlberg S; Nishino M; Sholl LM; Adeni A; Subegdjo S; Khosrowjerdi S; Peterson RM; Digumarthy S; Liu C; Sauter J; Rizvi H; Arbour KC; Carter BW; Heymach JV; Altan M; Hellmann MD; Awad MM
Ann Oncol; 2019 Oct; 30(10):1653-1659. PubMed ID: 31435660
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cortellini A; Tiseo M; Banna GL; Cappuzzo F; Aerts JGJV; Barbieri F; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Santini D; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Santoni M; Tudini M; Rijavec E; Filetti M; Catino A; Pizzutilo P; Sala L; Citarella F; Marco R; Torniai M; Cantini L; Targato G; Sforza V; Nigro O; Ferrara MG; D'Argento E; Buti S; Bordi P; Antonuzzo L; Scodes S; Landi L; Guaitoli G; Baldessari C; Della Gravara L; Dal Bello MG; Belderbos RA; Bironzo P; Carnio S; Ricciardi S; Grieco A; De Toma A; Proto C; Friedlaender A; Cantale O; Ricciuti B; Addeo A; Metro G; Ficorella C; Porzio G
Cancer Immunol Immunother; 2020 Nov; 69(11):2209-2221. PubMed ID: 32474768
[TBL] [Abstract][Full Text] [Related]
9. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
[TBL] [Abstract][Full Text] [Related]
10. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
[TBL] [Abstract][Full Text] [Related]
11. First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study.
Amrane K; Geier M; Corre R; Léna H; Léveiller G; Gadby F; Lamy R; Bizec JL; Goarant E; Robinet G; Gouva S; Quere G; Abgral R; Schick U; Bernier C; Chouaid C; Descourt R
Cancer Med; 2020 Apr; 9(7):2309-2316. PubMed ID: 32022459
[TBL] [Abstract][Full Text] [Related]
12. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
Imai H; Wasamoto S; Yamaguchi O; Suzuki K; Sugiyama T; Uchino J; Minemura H; Osaki T; Ishii H; Umeda Y; Mori K; Kotake M; Kagamu H; Morozumi N; Taniguchi H; Kasai T; Minato K; Kaira K
J Cancer Res Clin Oncol; 2020 Feb; 146(2):457-466. PubMed ID: 31853661
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Tamiya M; Tamiya A; Hosoya K; Taniguchi Y; Yokoyama T; Fukuda Y; Hirano K; Matsumoto H; Kominami R; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Kinoshita Y; Hara S; Kumagai T; Fujimoto D
Invest New Drugs; 2019 Dec; 37(6):1266-1273. PubMed ID: 31392549
[TBL] [Abstract][Full Text] [Related]
17. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab.
Friedlaender A; Metro G; Signorelli D; Gili A; Economopoulou P; Roila F; Banna G; De Toma A; Camerini A; Christopoulou A; Lo Russo G; Banini M; Galetta D; Jimenez B; Collazo-Lorduy A; Calles A; Baxevanos P; Linardou H; Kosmidis P; Mountzios G; Garassino MC; Addeo A
Acta Oncol; 2020 Sep; 59(9):1058-1063. PubMed ID: 32762415
[No Abstract] [Full Text] [Related]
18. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
[TBL] [Abstract][Full Text] [Related]
19. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B
Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203
[TBL] [Abstract][Full Text] [Related]
20. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Sezer A; Kilickap S; Gümüş M; Bondarenko I; Özgüroğlu M; Gogishvili M; Turk HM; Cicin I; Bentsion D; Gladkov O; Clingan P; Sriuranpong V; Rizvi N; Gao B; Li S; Lee S; McGuire K; Chen CI; Makharadze T; Paydas S; Nechaeva M; Seebach F; Weinreich DM; Yancopoulos GD; Gullo G; Lowy I; Rietschel P
Lancet; 2021 Feb; 397(10274):592-604. PubMed ID: 33581821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]